Anlon Healthcare shares had a muted debut, listing slightly above its IPO price after a nearly 7x subscription. The company plans to use the Rs 121 crore raised for expansion and debt reduction. Despite a limited operating history and regulatory risks, Anlon’s strong financial growth, expanding product portfolio, and regulatory approvals make it a compelling long-term investment.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets